 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
|
|
|
Phase II
|
|
|
|
MDA-2004-0059
6132, NCI-6132, NCT00104871
|
|
| |
17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
MAYO-MC0476
6482, NCI-6482, NCT00118248, JHOC-JS0652, JHOC-B/06/174
|
|
| |
Lenalidomide in Treating Patients With Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine and Cannot Be Removed By Surgery
|
|
|
|
Phase II
|
|
|
|
UKMC-05-0701-F3R
CELGENE-UKMC-05-0701-F3R, NCT00287287
|
|
| |
Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
|
|
|
Phase II
|
|
|
|
UCCRC-14696A
14696A, 7735, NCI-7735, NCT00381641
|
|
| |
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
A4061027
NCT00389441
|
|
| |
Sunitinib and Imaging Procedures in Treating Patients With Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
FHCRC-6494
UWCC-UW 6494, UWCC- 07-6030-H/B, 6494, PFIZER-FHCRC-6494, NCT00519896
|
|
| |
Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
Valproic Acid
NCT00525135
|
|
| |
Sorafenib in Treating Patients With Metastatic or Unresectable Resistant Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
UPCC-03305
UPCC#03305, UPCC-802861, NCT00601783
|
|
| |
Pazopanib in Treating Patients With Advanced Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
MAYO-MC057H
MC057H, 7627, NCT00625846
|
|
| |
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
WCI-2007-214
NCT00668811
|
|
